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Background: Patients with HER2-positive early breast cancer (EBC) preferred subcutaneous (s.c.) trastuzumab, deliv-
ered via single-use injection device (SID), over the intravenous (i.v.) formulation (Cohort 1 of the PrefHer study:
NCT01401166). Here, we report patient preference, healthcare professional satisfaction, and safety data pooled from
Cohort 1 and also Cohort 2, where s.c. trastuzumab was delivered via hand-held syringe.
Patients and methods: Patients were randomized to receive four adjuvant cycles of 600 mg ﬁxed-dose s.c. trastuzu-
mab followed by four cycles of standard i.v. trastuzumab, or vice versa. The primary endpoint was overall preference
proportions for s.c. or i.v., assessed by patient interviews in the evaluable ITT population.
Results: A total of 245 patients were randomized to receive s.c. followed by i.v. and 243 received i.v. followed by s.c.
(evaluable ITT populations: 235 and 232 patients, respectively). s.c. was preferred by 415/467 [88.9%; 95% conﬁdence
interval (CI) 85.7–91.6; P < 0.0001; two-sided test against null hypothesis of 65% s.c. preference]; 45/467 preferred i.v.
(9.6%; 95% CI 7–13); 7/467 indicated no preference (1.5%; 95% CI 1–3). Clinician-reported adverse events occurred in
292/479 (61.0%) and 245/478 (51.3%) patients during the pooled s.c. and i.v. periods, respectively (P < 0.05; 2 × 2 χ2);
16 patients (3.3%) in each period experienced grade 3 events; none were grade 4/5.
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Conclusions: PrefHer revealed compelling and consistent patient preferences for s.c. over i.v. trastuzumab, regardless
of SID or hand-held syringe delivery. s.c. was well tolerated and safety was consistent with previous reports, including the
HannaH study (NCT00950300). No new safety signals were identiﬁed compared with the known i.v. proﬁle in EBC.
PrefHer and HannaH conﬁrm that s.c. trastuzumab is a validated and preferred option over i.v. for improving patients’
care in HER2-positive breast cancer.
Clinicaltrials.gov registration number: NCT01401166.
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introduction
Trastuzumab-containing regimens are standard of care for
HER2-positive early breast cancer (EBC) and metastatic breast
cancer (MBC) [1–3]. A 600 mg ﬁxed-dose manual injection of
subcutaneous (s.c.) trastuzumab (Herceptin® SC, F. Hoffmann-
La Roche Ltd, Basel, Switzerland) given via hand-held syringe
is approved by the European Medicines Agency for EBC and
MBC as an alternative to conventional intravenous (i.v.) infu-
sion, based on noninferiority of trough serum concentration
(geometric mean ratio of 1.33) and pathologic complete re-
sponse (40.7% and 45.4% in the i.v. and s.c. groups, respectively)
in the phase III HannaH study (NCT00950300) [4]. An s.c.
single-use injection device (SID), which automatically delivers a
pre-inserted s.c. dose via a button press when attached to the
thigh, has comparable pharmacokinetics and safety to the hand-
held syringe [5].
Intuitively, s.c. trastuzumab should be more convenient for
patients as administration requires only 2–5 min [6]. Objectively,
reductions in patients’ infusion chair time, healthcare profes-
sionals’ time, and other hospital resources have been demon-
strated [7, 8]. The international, open-label, randomized, PrefHer
study (NCT01401166) examined patients’ preferences in the ad-
juvant breast cancer setting for i.v. or s.c. delivery via two cohorts
using both methods of s.c. trastuzumab administration (SID or
hand-held syringe) [9]. We present additional and ﬁnal results of
patient preferences in the overall study population (data pooled
from both cohorts).
methods
patients
Patient eligibility criteria have been described previously [9] and are available
in the supplementary material at Annals of Oncology online.
study design
After surgery and completion of (neo)adjuvant chemotherapy, patients
were randomized to receive four adjuvant cycles of s.c. trastuzumab (600
mg ﬁxed dose injected into the thigh over ∼5 min) every 3 weeks followed
by four cycles of i.v. (8 mg/kg loading dose if the patient was randomized
to receive i.v. trastuzumab ﬁrst, 6 mg/kg maintenance doses) every 3
weeks or vice versa (the crossover period, which was assessed in this
report) as part of their standard trastuzumab [9]. Stratiﬁcation was by de
novo and non-de novo trastuzumab groups. Patients received s.c. trastuzu-
mab via the SID in Cohort 1 and the hand-held syringe in Cohort
2. Following the crossover period, patients received i.v. trastuzumab in
Cohort 1 (unless participating in SID self-administration) and s.c. trastu-
zumab via hand-held syringe in Cohort 2. The primary endpoint was the
proportion of patients indicating an overall preference for s.c. or i.v. in
each cohort, assessed by two study-speciﬁc telephone patient interviews
(PINTs): one before randomization and one after the crossover period.
PINTs were conducted by experienced telephone interviewers and were
stringently quality-controlled to ensure impartial questioning. The ﬁrst
interview (PINT1) probed factors that could potentially inﬂuence prefer-
ences, such as previous experiences with drug delivery methods, needle
phobias, and expected preferences for s.c. or i.v. trastuzumab. The second
interview (PINT2) probed patients’ experiences with each administration
method on-study, ﬁnal preference, strength of the preference, and reasons
for it. Factors inﬂuencing preference, strength of the preference, and
reasons for it were exploratory endpoints. Patients in the SID cohort with
≥2 cycles remaining after crossover had the option to self-administer the
SID, their satisfaction being assessed by questionnaire after ﬁrst and last
self-administrations as an exploratory endpoint. Secondary endpoints
were safety and tolerability (assessed using standard methods [10–12]),
event-free survival, immunogenicity (anti-trastuzumab and anti-recom-
binant human hyaluronidase [rHuPH20] antibodies in blood samples,
taken at baseline and pre-dose cycle 5; assessed due to inclusion of
rHuPH20 in the s.c. formulation and the potential for Langerhans cell-
mediated immune reactions with s.c. injection) in the SID cohort, health-
care professional satisfaction (assessed by responses of gynecologists,
oncologists, oncology/specialist chemotherapy nurses, and other health-
care professionals to the questionnaire question, ‘All things considered
with which method of administration were you most satisﬁed?’ after the
crossover period), and healthcare professional-perceived time savings with
s.c. trastuzumab, also assessed by questionnaire.
PrefHer was conducted in accordance with Good Clinical Practice guide-
lines and the Declaration of Helsinki. All participating patients provided
written informed consent. Approval for the protocol was obtained from
appropriate local and national independent ethics committees.
statistical analyses
Preference for s.c. was compared in a nonprotocol-speciﬁed analysis with a
two-sided test against a null hypothesis value of 65% [9]. Each cohort was
powered independently. Factors potentially inﬂuencing preference were
assessed in terms of their effect on the primary endpoint using logistic re-
gression (forward selection by stepwise regression with α 0.05) in an explora-
tory manner.
Differences in adverse event (AE) rates were assessed using a 2 × 2 χ2 test.
Statistical analyses were carried out with SAS (version 9.1.3).
results
patients
From 27 October 2011 to 3 December 2012, 488 patients were
randomized (Figure 1). The safety population included 483
patients (ﬁve randomized patients did not receive study treat-
ment): 243 s.c.→ i.v. and 240 i.v.→ s.c. Twenty-four treated
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patients did not complete all eight trastuzumab cycles during
crossover owing to disease recurrence (nine patients), AEs
[grade 2 congestive heart failure (one patient), left ventricular
dysfunction (ﬁve patients: two grade 1, three grade 3), grade 2
arthralgia (one patient), grade 3 generalized erythema (one
patient)], refusal of treatment (three patients), withdrawal of
consent (two patients), loss to follow-up (one patient), and
protocol violation (one patient in the hand-held syringe cohort
with lung metastases was erroneously randomized and was
withdrawn after receiving one trastuzumab cycle). Of these
patients, eight received s.c. and i.v. and completed the primary
endpoint question in PINT2; therefore, they were included in
the evaluable ITT population. The remaining 16 patients did
not complete the primary endpoint question; therefore, the eva-
luable ITT population comprised 467 patients (235 patients
s.c.→ i.v. and 232 i.v.→ s.c.). No data were missing as all evalu-
able ITT patients completed both PINTs.
Baseline patient demographics, tumor characteristics, and
treatment history were balanced between study arms (Table 1).
patient preference
primary endpoint. At PINT2, 88.9% of patients (415/467)
preferred s.c. [95% conﬁdence interval (CI) 85.7–91.6;
P < 0.0001, two-sided test against the null hypothesis of 65% s.c.
preference], 9.6% (45/467, 95% CI 7.1–12.7) preferred i.v., and
1.5% (7/467, 95% CI 0.6–3.1) had no preference (Figure 2).
Results were consistent in both study arms: s.c.→ i.v. arm,
89.8% of patients (211/235, 95% CI 85.2–93.3) preferred s.c.,
8.9% (21/235, 95% CI 5.6–13.3) preferred i.v., and 1.3% (3/235,
523 patients completed the first interview
35 excluded
• 1 administrative failure
• 1 decided not to participate
• 1 disease progression
• 28 failed eligibility criteria
• 1 screened outside of the
   prespecified screening period 
• 3 withdrew consent
488 patients randomized at 74 centers in 12
countries across Europe and Canada 
2 patients
not treated 
• 1 investigator decision
• 1 missing
Arm A: s.c.Æi.v.
243 safety
populationb 
3 patients
not treated 
• 1 adverse event
• 1 disease recurrence
• 1 screen failurea
Arm B: i.v.Æs.c.
240 safety
populationb 
Arm A: s.c.Æi.v.
235 evaluable 
ITT populationc
8 patients
discontinued
treatment 
• 4 adverse events
• 2 disease recurrences
• 1 lost to follow-up
• 1 refused treatment
Arm B: i.v.Æs.c.
232 evaluable
ITT populationc
8 patients
discontinued
treatment 
• 1 adverse event
• 4 disease recurrences
• 1 refused treatment
• 1 withdrew consent
• 1 protocol violation
Arm B: i.v.Æs.c.
243 randomized 
Arm A: s.c.Æi.v.
245 randomized
Figure 1. Trial proﬁle. aPatient was screened and randomized but was later found to have a left ventricular ejection fraction of 53%. No treatment was given
on-trial. bPatients who received at least one dose of study treatment. cPatients who received at least one dose of s.c. trastuzumab and i.v. trastuzumab and
completed PINT1 and the primary endpoint question in PINT2. ITT, intention-to-treat; i.v., intravenous; PINT, patient interview; s.c., subcutaneous.
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95% CI 0.3–3.7) had no preference; i.v.→ s.c. arm, 87.9% of
patients (204/232, 95% CI 83.0–91.8) preferred s.c., 10.3% (24/
232, 95% CI 6.7–15.0) preferred i.v., and 1.7% (4/232, 95% CI
0.5–4.4) had no preference.
exploratory analysis: strength of preferences. Overall preference
for s.c. was ‘very strong’ in 64.9% of patients (303/467; 95% CI
60.4–69.2), ‘fairly strong’ in 17.3% (81/467, 95% CI 14.0–21.1),
and ‘not very strong’ in 6.6% (31/467, 95% CI 4.6–9.3). Overall
preference for i.v. was ‘very strong’ in 5.1% of patients (24/467,
95% CI 3.3–7.6), ‘fairly strong’ in 2.1% (10/467, 95% CI 1.0–
3.9), and ‘not very strong’ in 2.4% (11/467, 95% CI 1.2–4.2).
exploratory analysis: reasons for patients’ preferences. The two
main reasons that patients gave for preferring s.c. when asked in
an open-ended question were that it saved time and that it
resulted in less pain/discomfort/side effects (Table 2). When
speciﬁcally asked about pain and bother from bruising or
irritation to the injection site, patients reported that s.c. was the
least painful [60.6% (283/467 patients) versus 17.3% for i.v. (81/
467); 22.1% (103/467) reported no difference], and caused less
bother from bruising [41.1% (192/467) versus 16.1% (75/467);
42.8% (200/467) reported no difference], or irritation to the
injection site [33.0% (154/467) versus 14.6% (68/467); 52.5%
(245/467) reported no difference].
predeﬁned exploratory endpoint: factors inﬂuencing preference.
There was a high preference by patients for s.c. trastuzumab
regardless of whether they had received i.v. trastuzumab before
enrollment (Figure 2).
Four terms were found to be signiﬁcant and therefore kept in
the ﬁnal stepwise logistic regression model to select factors that
potentially inﬂuence preference (supplementary Table S1, avail-
able at Annals of Oncology online): expected preferences given at
PINT1 [odds ratio (OR) 2.98, 95% CI 1.51–5.88], weight (OR
0.41, 95% CI 0.17–0.97), needle phobia/anxiety (OR 0.31, 95%
CI 0.14–0.68), and i.v. delivery type for prior chemotherapy
(OR 2.31, 95% CI 1.21–4.41). However, these results should be
interpreted with caution due to the low number of patients who
expressed a preference for i.v. or expressed no preference.
Hypothetical preference from PINT1 was a factor that
inﬂuenced ﬁnal preferences. Of the patients who expressed a
prior preference for s.c., 94.0% (203/216) expressed a ﬁnal pref-
erence for s.c. (Table 3). Of the patients who expressed a prior
preference for i.v. or expressed no prior preference, 84.5% (212/
251) expressed a ﬁnal preference for s.c.
Preference for s.c. was 91.5% (95% CI 87.4–94.6) for patients
receiving i.v. trastuzumab by cannula (236/258 patients), 85.8%
(95% CI 80.2–90.3) for those with a venous access device (175/
204 patients), and 80.0% (95% CI 28.4–99.5) for those who
received i.v. trastuzumab by both venous access methods (4/5
patients). Patients also preferred s.c. over i.v. regardless of their
country (supplementary Table S2, available at Annals of Oncology
online).
exploratory analysis: hypothetical preferred location and route of
trastuzumab administration. Overall, 60.4% of patients (282/
467, 95% CI 55.8–64.9) expressed a hypothetical preference to
receive s.c. at home [65.7% in the SID cohort (155/236, 95% CI
59.2–71.7) and 55.0% in the hand-held syringe cohort (127/231,
95% CI 48.3–61.5)] when asked during PINT2 (supplementary
Table S3, available at Annals of Oncology online).
secondary endpoint: healthcare professional satisfaction. Two
hundred thirty-ﬁve healthcare professional questionnaires were
completed. Responses indicated that most respondents were
more satisﬁed with s.c. administration [77.0% (181/235), 95%
CI 71.1–82.2] than with i.v. [3.0% (7/235), 95% CI 1.2–6.0]. The
remaining 20.0% [(47/235), 95% CI, 15.1–25.7] indicated no
preference for either route.
Table 1. Patient demographics, tumor characteristics, and
treatment history (evaluable intention-to-treat population)
Arm A
s.c.→ i.v.
n = 235
Arm B
i.v.→ s.c.
n = 232
Age, yearsa
Median 53.0 52.0
(min–max) (29–78) (27–76)
Weight, kg
Median 68.0 66.0
(min–max) (35.0–120.0) (41.0–131.8)
ECOG at screening, n (%)
0 194 (82.6) 187 (80.6)
1 41 (17.4) 44 (19.0)
Not done 0 1 (0.4)
TNM classiﬁcation at diagnosis, n (%)
Primary tumorb
T0–T2 208 (88.5) 195 (84.1)
T3–T4 22 (9.4) 37 (15.9)
Not assessable/unknown 5 (2.1) 0
Lymph node status, n (%)
Negative 119 (50.6) 110 (47.4)
Positive 109 (46.4) 118 (50.9)
Not assessable/unknown 7 (3.0) 4 (1.7)
Trastuzumab before enrollment, n (%)
De novo 47 (20.0) 47 (20.3)
Non-de novo 188 (80.0) 185 (79.7)
Previous treatment, n (%)
Chemotherapy 234 (99.6) 232 (100)
Radiotherapy 145 (61.7) 141 (60.8)
Hormonal therapy 96 (40.9) 95 (40.9)
Lapatinib 0 2 (0.9)
All patients received prior surgery. Two hundred twenty-four patients
(48.0%) received prior i.v. chemotherapy via cannula, 206 (44.1%)
received prior i.v. chemotherapy via a venous access device, and 37
(7.9%) received prior i.v. chemotherapy via both methods.
aThere were 331 patients who were younger than 60 years and 136 who
were 60 years or older.
bPatients with T4 tumors received (neo)adjuvant chemotherapy and
were eligible for the study.
ECOG, Eastern Cooperative Oncology Group; HER2, human epidermal
growth factor receptor 2; i.v., intravenous; s.c., subcutaneous.
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secondary endpoint: AE proﬁle. The AE proﬁle obtained during
the crossover period at this interim safety analysis is shown in
Table 4. Differences between rates in the pooled s.c. and i.v.
periods were driven by grade 1 events occurring more
frequently during the s.c. period. Inﬂuenza, dermatitis, syncope,
hypertension, left ventricular dysfunction, and dyspnea were the
most common grade 3 AEs [0.4% of patients (two) each]. No
patients had a grade 4 or 5 AE. No serious AEs were considered
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Figure 2. Patients’ preferences (evaluable intention-to-treat population). Responses to the question ‘All things considered, which method of administration
did you prefer?’ Error bars represent 95% conﬁdence intervals. i.v., intravenous; s.c., subcutaneous.
Table 2. Primary reasons for patients’ preferences (evaluable intention-to-treat population)
Reason category Total,
n (%)a
Example
s.c. preferred, n = 756 reasons given by 415 patients
Time saving 375 (80.3) ‘It does affect me being there so many hours.
With this it was ‘Hello’ and ‘Bye’ without having to spend hours with patients’
Less pain/discomfort/side effects 160 (34.3) ‘The s.c. method was a lot less painful to me and my bruises faded faster than in the case of the
intravenous method’
Ease of administration 62 (13.3) ‘Nurses can take care of many patients at the same time’
Convenience to patient 57 (12.2) ‘Busy mum with four young children— want to get on with life’
Problems with i.v. 51 (10.9) ‘No veins to be found as my veins are collapsing’
Less stress/anxiety 35 (7.5) ‘i.v. reminds one of chemo and isn’t very pleasant for the head’
Other 20 (4.3) ‘Safer — less risk of infections’b
i.v. preferred, n = 64 reasons given by 45 patients
Fewer reactions (less pain, bruising,
irritation, etc.)
33 (7.1) ‘Irritation due to the s.c.’
Other/don’t know 10 (2.1) ‘Had to have the port ﬂushed through when attending for s.c. sessions, so would have been
easier just to use it anyway’
Psychological 9 (1.9) ‘When you have i.v., you arrive, settle yourself. You have about 30 minutes. You can discuss
with the nurses and other patients. It’s a feeling of being “at home.”’
Perceived efﬁcacy 6 (1.3) ‘I’m not quite convinced that s.c. has the same effect as i.v.’b
Environment/staff 5 (1.1) ‘One has to go there anyway and one can sit there with other women and exchange experience’
Ecological considerations 1 (0.2) ‘Device is not environmentally sustainable. It is all thrown away after use’
Responses to the question ‘What are the two main reasons for your preference?’ were recorded verbatim by the interviewer. Four experienced
researchers independently scrutinized the dataset and provided overarching themes or core categories for coding. When broad consensus about these
had been reached, each researcher independently coded every patient’s response; the researchers then reconciled codings with each other and
determined if any thematic categories could reasonably be collapsed together or if a new category was required.
aSome patients gave only one reason or no reason. Percentages were calculated on a per-patient basis (N = 467).
bStatement based on patient preference and not reﬂective of clinical data.
i.v., intravenous; s.c., subcutaneous.
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to be related to trastuzumab and each was resolved without
sequelae. Twenty-four of 483 patients experienced cardiac
events, but only two instances were recorded as grade 3 (both
were left ventricular dysfunction). No cardiac events were
reported as serious and there was one case of congestive heart
failure (grade 2; resolved without sequelae).
secondary endpoint: immunogenicity. In the s.c.→ i.v. and
i.v.→ s.c. arms, anti-trastuzumab antibody rates were 0% [0/114
evaluable patients (any patient with a pre-dose cycle 5
trastuzumab or rHuPH20 antibody result regardless of baseline
result)] and 3.4% (4/119), respectively, and the anti-rHuPH20
antibody rates were 2.6% (3/115) and 7.6% (9/119), respectively
(supplementary Table S4, available at Annals of Oncology online).
No association between AEs and the presence of anti-trastuzumab
or -rHuPH20 antibodies was observed (data not shown).
discussion
Final preference results from PrefHer showed that patients
strongly preferred s.c. trastuzumab, regardless of SID or hand-
held syringe delivery. These data provide an impetus for a
change in practice regarding trastuzumab administration, and
patients should be offered the choice of route. Patients should
be provided with timely, accurate and easily understandable
information regarding the available routes of administration,
and with the evidence base accumulated showing the experi-
ences and preference of patients who received both i.v. and s.c.
Future trial designs (including in MBC) might use the method-
ology employed in PrefHer, where appropriate, with patient pre-
ferences and the reasons for them assessed as an essential part
of the protocol.
Patients consistently gave ‘time saving’ as their main reason for
s.c. preference [9, 13, 14], which was conﬁrmed by quantitative
data from a time-and-motion sub-study [7, 8]. The SID may save
patients further time by potentially allowing self-administration
at home: the location hypothetically preferred by almost two-
thirds of the patients in the SID cohort.
s.c. trastuzumab was well tolerated and no new safety signals
were identiﬁed compared with the known i.v. proﬁle in EBC.
Additional analyses of PrefHer have shown that the safety
proﬁle combined from both cohorts is not affected by switching
from s.c. to i.v. or vice versa [15], further supporting a change
for patients who prefer this method. As with HannaH [16], tras-
tuzumab and rHuPH20 anti-drug antibody rates were low and
there was no correlation with safety; however, results should be
interpreted with caution as anti-trastuzumab antibody rates may
have been underestimated due to the presence of trastuzumab in
the serum affecting detection of anti-trastuzumab antibodies in
the assay, and due to the fact that assessment was carried out after
only four cycles of exposure. HannaH will assess immunogenicity
up to 60 months post-treatment [17] and SafeHer will further
assess immunogenicity with the SID [18].
Interpretation of safety analyses should also take into account
the limitations of having a short period of time during which
the events were recorded for this analysis (eight 3-weekly
cycles). Future analyses will assess data from the continuation
periods once all patients have completed follow-up.
The apparent discrepancy between increased clinician-
reported AEs during the s.c. period and patients’ reports of s.c.
producing less pain, bruising, and irritation may have resulted
from a more conservative approach to reporting due to inexperi-
ence with the s.c. formulation [4].
Healthcare professionals were more satisﬁed with s.c. regard-
less of administration method. The time-and-motion sub-study
has shown that healthcare professional time and center costs
may be substantially reduced using the SID or the hand-
held syringe [7, 8], and that healthcare professional-perceived
clinical management and efﬁciency was increased with either
s.c. method, to the beneﬁt of different stakeholders [8, 19].
Combined with the totality of the clinical and patient preference
data, s.c. trastuzumab has been shown to provide beneﬁts to
both patients and healthcare systems.
In conclusion, PrefHer revealed compelling and consistent
patient preference for s.c. trastuzumab, regardless of delivery
method (SID or hand-held syringe). Healthcare professionals
were also more satisﬁed with s.c. over i.v. administration and s.c.
was well tolerated. Safety data, including immunogenicity, were
consistent with previous reports and no new safety signals were
identiﬁed compared with the known i.v. proﬁle in EBC.
Table 3. Expected and actual preferences (evaluable intention-to-treat population)
PINT1: preferred method of administration
i.v.
n = 46
s.c.
n = 216
No preference
n = 205
Overall
N = 467
PINT2: preferred method of administration, n (%)
i.v. 11 (23.9) 12 (5.6) 22 (10.7) 45 (9.6%)
s.c. 33 (71.7) 203 (94.0) 179 (87.3) 415 (88.9%)
No preference 2 (4.3) 1 (0.5) 4 (2.0) 7 (1.5%)
s.c. preferred (exact binomial)
Estimated proportion 71.7 94.0 87.3 88.9
95% CI 56.5–84.0 89.9–96.8 82.0–91.5 85.7–91.6
CI, conﬁdence interval; i.v., intravenous; PINT, patient interview; s.c., subcutaneous.
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Based on data from HannaH and PrefHer, s.c. trastuzumab is
the validated and preferred option over i.v. for improving patients’
care in HER2-positive breast cancer.
acknowledgements
We thank the individuals who contributed to the design of the
study instruments, the patients, their families, the nurses, the
interviewers, and the investigators who participated in this
study. We also thank Rebecca Elliot of Genentech, Inc. (South
San Francisco, CA) for immunogenicity analyses. Support for
third-party writing assistance for this manuscript, furnished by
Daniel Clyde, PhD, was provided by F. Hoffmann-La Roche Ltd.
funding
This work was supported by F. Hoffmann-La Roche Ltd, Basel,
Switzerland.
disclosure
XP has held consultant/advisory roles for F. Hoffmann-La
Roche Ltd, GlaxoSmithKline, and Teva, and has received honor-
aria from Sanoﬁ-Aventis and Eisai. JG has held consultant/
Table 4. Adverse event proﬁle during the crossover period
(four cycles of s.c. trastuzumab and four cycles of i.v. trastuzumab,
safety population)
s.c. period
(all arms
pooled)
n = 479
i.v. period
(all arms
pooled)
n = 478
Adverse events (all NCI-CTCAE
grades), n (%)
292 (61.0)a 245 (51.3)a
Grade 1 (mild) 253 (52.8) 195 (40.8)
Grade 2 (moderate) 116 (24.2) 106 (22.2)
Grade 3 (severe) 16 (3.3) 16 (3.3)
Grade 4 (life-threatening) 0 0
Grade 5 (death) 0 0
Most frequent adverse events (≥5% of patients in
the s.c., i.v., or crossover periods, all NCI-CTCAE grades), n (%)
Arthralgia 24 (5.0) 27 (5.6)
Grade 1 (mild) 20 (4.2) 22 (4.6)
Grade 2 (moderate) 4 (0.8) 5 (1.0)
Asthenia 27 (5.6) 23 (4.8)
Grade 1 (mild) 15 (3.1) 18 (3.8)
Grade 2 (moderate) 12 (2.5) 5 (1.0)
Hot ﬂush 23 (4.8) 16 (3.3)
Grade 1 (mild) 16 (3.3) 10 (2.1)
Grade 2 (moderate) 7 (1.5) 6 (1.3)
Fatigue 19 (4.0) 18 (3.8)
Grade 1 (mild) 13 (2.7) 12 (2.5)
Grade 2 (moderate) 6 (1.3) 6 (1.3)
Grade 3 (severe) 0 1 (0.2)
Nausea 25 (5.2) 14 (2.9)
Grade 1 (mild) 20 (4.2) 12 (2.5)
Grade 2 (moderate) 4 (0.8) 2 (0.4)
Grade 3 (severe) 0 0
Missing 1 (0.2) 0
Headache 20 (4.2) 16 (3.3)
Grade 1 (mild) 14 (2.9) 12 (2.5)
Grade 2 (moderate) 6 (1.3) 3 (0.6)
Grade 3 (severe) 0 1 (0.2)
Injection site pain 32 (6.7) 0
Grade 1 (mild) 28 (5.8) 0
Grade 2 (moderate) 4 (0.8) 0
Injection site reaction 30 (6.3)b 0
Grade 1 (mild) 29 (6.1) 0
Grade 2 (moderate) 4 (0.8) 0
Injection site erythema 27 (5.6) 0
Grade 1 (mild) 24 (5.0) 0
Grade 2 (moderate) 3 (0.6) 0
Diarrhea 16 (3.3)c 12 (2.5)
Grade 1 (mild) 12 (2.5) 10 (2.1)
Grade 2 (moderate) 5 (1.0) 2 (0.4)
Pain in extremity 18 (3.8) 7 (1.5)
Grade 1 (mild) 17 (3.5) 2 (0.4)
Grade 2 (moderate) 1 (0.2) 5 (1.0)
Serious adverse events
(ICH E2A), n (%)d
4 (0.8) 4 (0.8)
Continued
Table 4. Continued
s.c. period
(all arms
pooled)
n = 479
i.v. period
(all arms
pooled)
n = 478
Study drug discontinued due
to adverse events, n (%)
5 (1.0) 6 (1.3)
If a patient had multiple events of the same NCI-CTCAE grade or
relationship category, they were counted only once in that NCI-
CTCAE grade or relationship category.
Patients could be counted in both the s.c. and i.v. period columns.
a2 × 2 χ2, P < 0.05.
bThree patients had both grade 1 (mild) and grade 2 (moderate)
injection site reactions and so are counted once in each NCI-CTCAE
grade and once overall.
cOne patient had both grade 1 (mild) and grade 2 (moderate)
diarrhea and so is counted once in each NCI-CTCAE grade and once
overall.
dBreast expander infection, axilla abscess, benign breast adenoma,
and hematoma (not at the injection site) during the s.c. period
and wound infection, inﬂuenza, cholelithiasis, suture-related
complication (post-laparotomy), and mental disorder during the i.v.
period. All were reported in one patient each (0.2%), none were
related to study treatment, and all resolved fully without sequelae.
ICH, International Conference on Harmonisation; i.v., intravenous;
NCI-CTCAE, National Cancer Institute–Common Terminology
Criteria for Adverse Events; s.c., subcutaneous.
Volume 25 | No. 10 | October 2014 doi:10.1093/annonc/mdu364 | 
Annals of Oncology original articles
advisory roles for F. Hoffmann-La Roche Ltd, Teva, and Eisai,
and has received honoraria from F. Hoffmann-La Roche Ltd,
GlaxoSmithKline, and Novartis. VM has held consultant/advis-
ory roles for Amgen, Celgene, and F. Hoffmann-La Roche Ltd,
and has received honoraria from Amgen, Celgene, Pierre-Fabre,
F. Hoffmann-La Roche Ltd, and Janssen-Cilag. AK has held
consultant/advisory roles for, and has received honoraria from,
F. Hoffmann-La Roche Ltd. SV has held consultant/advisory
roles for, and has received honoraria from, F. Hoffmann-La
Roche Ltd, Novartis, and Amgen, and has received research
funding from F. Hoffmann-La Roche Ltd and Sanoﬁ-Aventis.
NS is an employee of, and holds stocks in, F. Hoffmann-La
Roche Ltd. SO is an employee of F. Hoffmann-La Roche Ltd. LF
has held consultant/advisory roles for, and has received honor-
aria and research funding from, F. Hoffmann-La Roche Ltd. GC
and VJ have no conﬂicts of interest to disclose.
references
1. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in
Oncology: Breast Cancer 2014. V3.2014. http://www.nccn.org/ (14 April 2014,
date last accessed).
2. Senkus E, Kyriakides S, Penault-Llorca F et al. Primary breast cancer: ESMO
Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol
2013; 24: vi7–vi23.
3. Goldhirsch A, Winer EP, Coates AS et al. Personalizing the treatment of women
with early breast cancer: highlights of the St Gallen International Expert Consensus
on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol 2013; 24:
2206–2223.
4. Ismael G, Hegg R, Muehlbauer S et al. Subcutaneous versus intravenous
administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical
stage I–III breast cancer (HannaH study): a phase 3, open-label, multicentre,
randomised trial. Lancet Oncol 2012; 13: 869–878.
5. Wynne C, Ellis-Pegler RB, Waaka DS et al. Comparative pharmacokinetics of
subcutaneous trastuzumab administered via handheld syringe or proprietary
single-use injection device in healthy males. Cancer Chemother Pharmacol 2013;
72: 1079–1087.
6. Herceptin 600 mg/5 ml solution for injection summary of product characteristics.
Roche Products Limited. http://www.medicines.org.uk/emc/medicine/28179/SPC/
Herceptin+600+mg+5+ml+Solution+for+Injection/ (25 March 2014, date last
accessed).
7. De Cock E, Knoop A, Jakobsen EH et al. Manual injection of subcutaneous
trastuzumab vs intravenous infusion for HER2-positive early breast cancer: a time-
and-motion study. Eur J Cancer 2013; 49: S432. Abstract 1955.
8. Burcombe R, Chan S, Simcock R et al. Subcutaneous trastuzumab (Herceptin®): a
UK time and motion study in comparison with intravenous formulation for the
treatment of patients with HER2-positive early breast cancer. Adv Breast Cancer
Res 2013; 2: 133–140.
9. Pivot X, Gligorov J, Müller V et al. Preference for subcutaneous or intravenous
administration of trastuzumab in patients with HER2-positive early breast cancer
(PrefHer): an open-label randomised study. Lancet Oncol 2013; 14: 962–970.
10. National Cancer Institute Common Terminology Criteria for Adverse Events version
4.0. 2009. http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_Quick
Reference_5x7.pdf (31 January 2014, date last accessed).
11. The Criteria Committee for the New York Heart Association. Nomenclature and
Criteria for Diagnosis of Diseases of the Heart and Great Vessels, 9th edition.
New York: Little, Brown and Company, 1994.
12. ICH Harmonised Tripartite Guideline. Clinical safety data management: deﬁnitions
and standards for expedited reporting E2A. 1995.
13. Pivot X, Gligorov J, Müller V et al. Patient preference for subcutaneous
trastuzumab via handheld syringe versus intravenous infusion in HER2-positive
early breast cancer: cohort 2 of the PrefHer study; abstract P4-12-11. Cancer Res
2013; 73 (24 Suppl).
14. Fallowﬁeld L, Jenkins V, Kilkerr J et al. Reasons for patients’ preferences for
subcutaneous or intravenous trastuzumab in the PrefHer study. Eur J Cancer
2013; 49: S385. Abstract 1759.
15. Gligorov J, Curigliano G, Müller V et al. Assessment of adverse events in patients
switching between trastuzumab administration routes (subcutaneous to
intravenous and intravenous to subcutaneous) in the PrefHer study. In: 9th
European Breast Cancer Conference, Glasgow, Scotland, 2014. Abstract 229.
16. Hegg R, Pienkowski T, Chen S-C et al. Immunogenicity of trastuzumab intravenous
and subcutaneous formulations in the Phase III HannaH study; abstract 273P. Ann
Oncol 2012; 23: ix95–ix115.
17. A study to compare subcutaneous versus intravenous administration of herceptin
(trastuzumab) in women with HER2-positive early breast cancer. Hoffmann-La
Roche; http://clinicaltrials.gov/ct2/show/NCT00950300 (14 July 2014, date last
accessed).
18. Gligorov J, Azim HA, Ataseven B et al. SafeHer: A study of assisted- and self-
administered subcutaneous trastuzumab (H-SC) as adjuvant therapy in patients
with early HER2-positive breast cancer (EBC). Ann Oncol 2012; 23: ix95–ix115.
Abstract 315TiP.
19. De Cock E, Pan I, Sandoval M et al. Healthcare professionals’ perceptions of the
impact on clinical management of switching from the intravenous to the
subcutaneous formulation of trastuzumab. In: 9th European Breast Cancer
Conference, Glasgow, Scotland, 2014. Abstract 42.
appendix
Sussex Health Outcomes Research &
Education in Cancer (SHORE-C)
PrefHer study team
Lesley Fallowﬁeld; Valerie Jenkins; Justine Kilkerr; Carolyn
Langridge; Kathryn Monson.
PrefHer study investigators
Europe
Denmark. Erik Hugger Jakobsen (Vejle Sygehus)
Mette Holck Nielsen (Odense Universitetshospital)
Soeren Linnet (Regionshospitalet Herning)
Ann Knoop (Copenhagen University Hospital)
France. Xavier Pivot (University Hospital Jean Minjoz).
Herve Bonnefoi (Institut Bergonié)
Mireille Mousseau (Hôpital Albert Michallon)
Laurent Zelek (Hôpital Avicenne)
Hugues Bourgeois (Clinique Victor Hugo)
Claudia Plesse Lefeuvre (Centre Eugène Marquis)
Thomas Bachelot (Centre Léon Bérard)
Thierry Petit (Centre Paul Strauss)
Etienne Brain (Centre René Huguenin)
Christelle Levy (CRLCC-François Baclesse)
Joseph Gligorov (APHP Hôpital Tenon)
Germany. Doris Augustin (Donauisar Klinikum Deggendorf)
Heiko Graf (Klinikum Meiningen Klinik für Gynäkologie und
Geburtshilfe)
Georg Heinrich (Schwerpunktpraxis Dr. med. Georg
Heinrich)
Hendrik Kroening (Onkologische Gemeinschaftspraxis)
Sherko Kuemmel (Klinikum Essen-Mitte Ev. Huyssens-
Stiftung/Knappschafts GmbH)
 | Pivot et al. Volume 25 | No. 10 | October 2014
original articles Annals of Oncology
Volkmar Müller (University Medical Center Hamburg-
Eppendorf )
Friedrich Overkamp (Praxis für Onkologie und Hämatologie)
Tjoung-Won Park-Simon (Medizinische Hochschule Hannover,
Klinik für Frauenheilkunde und Geburtshilfe)
Marcus Schmidt (Uniklinik Mainz)
Lidia Perlova-Griff (Sankt Gertrauden-Krankenhaus
Brustzentrum)
Christopher Wolf (Dres. Christopher Wolf und Alfred Wolf)
Italy. Marco Colleoni (IRCCS Istituto Europeo Di Oncologia
(IEO))
Alberto Ballestrero (Uni Degli Studi Di Genova)
Antonio Bernardo (IRCCS Fondazione Maugeri)
Angela Stefania Ribecco (Azienda Sanitaria di Firenze–Ospedale
Santa Maria Annunziata, SCOncologia Medica)
Luca Gianni (Oncologia Medica, Ospedale San Raffaele)
Giuseppe Curigliano (European Institute of Oncology)
Poland. Elżbieta Brewczynska (Maria Sklodowska-Curie
Memorial Cancer Center and Institute of Oncology)
Jacek Jassem (Uniwersyteckie Centrum Kliniczne, Klinika
Onkologii i Radioterapii)
Russia. Vadim Shirinkin (State Institute of Healthcare Orenburg
Regional Clinical Oncology Dispensary)
Alexey Manikhas (City Oncology Dispensary)
Victoria Dvornichenko (Regional Oncology Hospital)
Mikhail Lichinitser (Blokhin Cancer Research Center)
Vladimir Semiglazov (NN Petrov Research Institute of
Oncology)
Guzel Mukhametshina (Republican Clinical Oncologic
Dispensary of Republic of Tatarstan)
Irina Bulavina (Sverdlovsk Regional Oncology Dispensary)
Spain. Enrique Espinosa Arranz (Hospital Universitario La Paz)
Francisco Carabantes Ocon (Hospital Regional Universitario
Carlos Haya)
Guillermo López Vivanco (University Hospital Cruces, San
Vicente de Barakaldo, Vizcaya)
Javier Salvador Boﬁll (Hospital Universitario Nuestra Señora
de Valme)
Ignacio Porras Quintela (Hospital Universitario Reina Soﬁa)
Alfonso Sanchez Muñoz (Hospital Clínico Universitario
Virgen de la Victoria)
Yolanda Fernández Pérez (Hospital Univ. Central de Asturias)
Javier Cassinello Espinosa (Hospital General Universitario de
Guadalajara)
José Valero Alvarez (Complejo Hospitalario Zamora –
Hospital Virgen de la Concha)
Rodrigo Lastra del Prado (Hospital General de San Jorge)
Luis De La Cruz Merino (Hospital Universitario Virgen
Macarena)
José Manuel Pérez García (Hospital Quirón Barcelona)
Santos Enrech Frances (Hospital Universitario de Getafe)
Sweden. Per Edlund (Gävle Sjukhus)
Bengt Norberg (Länssjukhuset Ryhov)
Anna-Karin Wennstig (Länssjukhuset Sundsvall)
Pehr Lind (Mälarsjukhuset)
Switzerland. Nik Hauser (Kantonsspital Baden AG)
Christoph Tausch (Brustzentrum)
Turkey. Celalettin Camci (Gaziantep University Medical Faculty)
Fikret Arpaci (GATA)
Huseyin Abali (Adana Baskent University Hospital)
Ruchan Uslu (Ege University Medical Faculty)
United Kingdom. Saad Tahir (Broomﬁeld Hospital)
Duncan Wheatley (Royal Cornwall Hospital)
Stephen Chan (Nottingham City Hospital)
Peter Barrett-Lee (Velindre Cancer Centre)
Karen McAdam (Peterborough District Hospital)
Richard Simcock (Brighton and Sussex University Hospital)
Russell Burcombe (Maidstone and Tunbridge Wells Hospital)
Canada
Robert El-Maraghi (Royal Victoria Regional Health Centre)
Nadia Califaretti (Grand River Regional Cancer Centre)
Silvana Spadafora (Algoma Regional Cancer Program, Sault
Area Hospital)
Sandeep Sehdev (William Osler Health System Brampton
Civic Hospital)
Amer Sami (Saskatoon Cancer Centre, University of Saskatoon
Campus)
Sunil Verma (Sunnybrook Odette Cancer Centre)
Volume 25 | No. 10 | October 2014 doi:10.1093/annonc/mdu364 | 
Annals of Oncology original articles
